Emerging targeted therapies for castration-resistant prostate cancer

Emerging targeted therapies for castration-resistant prostate cancer

Until recently, few therapeutic options were available for patients with castration-resistant prostate cancer (CRPC). Since 2010, four new molecules with a demonstrated benefit (sipuleucel-T, cabazitaxel, abiraterone and denosumab) have been approved in this setting, and to-date several other agents...

Full description

Bibliographic Details
Main Authors: Vincenzo eAdamo, Laura eNoto, Tindara eFranchina, Giuseppe eChiofalo, Maria ePicciotto, Giuseppe eToscano, Nicola eCaristi
Format: Article
Language:English
Published: Frontiers Media S.A. 2012-05-01
Series:Frontiers in Endocrinology
Subjects:
Immunotherapy
castration-resistant prostate cancer
targeted therapy
hormonal therapy
antiangiogenic therapy
bone targeting therapy
Online Access:http://journal.frontiersin.org/Journal/10.3389/fendo.2012.00073/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fendo.2012.00073/full

Similar Items